BRIEF-MannKind To Acquire scPharmaceuticals

Reuters08-25

Aug 25 (Reuters) - MannKind Corp MNKD.O:

MANNKIND TO ACQUIRE SCPHARMACEUTICALS, ACCELERATING REVENUE GROWTH AND EMERGING AS A PATIENT-CENTRIC LEADER IN CARDIOMETABOLIC AND LUNG DISEASES
MANNKIND CORP - DEAL FOR UPFRONT CASH PAYMENT OF $5.35 PER SHARE PLUS CVR
MANNKIND CORP - TOTAL EQUITY VALUE $303 MILLION, DEAL VALUE UP TO $360 MILLION
MANNKIND CORP - CO AND BLACKSTONE AMEND FINANCING AGREEMENT FOR $175 MILLION

Source text: ID:nGNX4Dd9pp

Further company coverage: MNKD.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2562324652?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-25 19:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2562324652","market":"us","top_or_hot":-1,"title":"BRIEF-MannKind To Acquire scPharmaceuticals","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-MannKind To Acquire scPharmaceuticals</title></head><body><p><span>Aug 25 (Reuters)</span><span> - </span>MannKind Corp <span>MNKD.O</span>:</p><ul><li><p>MANNKIND TO ACQUIRE SCPHARMACEUTICALS, ACCELERATING REVENUE GROWTH AND EMERGING AS A PATIENT-CENTRIC LEADER IN CARDIOMETABOLIC AND LUNG DISEASES</p></li><li><p>MANNKIND CORP - DEAL FOR UPFRONT CASH PAYMENT OF $5.35 PER SHARE PLUS CVR</p></li><li><p>MANNKIND CORP - TOTAL EQUITY VALUE $303 MILLION, DEAL VALUE UP TO $360 MILLION</p></li><li><p>MANNKIND CORP - CO AND BLACKSTONE AMEND FINANCING AGREEMENT FOR $175 MILLION</p></li></ul><p>Source text: <span>ID:nGNX4Dd9pp</span></p><p>Further company coverage: <span>MNKD.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-MannKind To Acquire scPharmaceuticals</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-MannKind To Acquire scPharmaceuticals\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-25 19:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-MannKind To Acquire scPharmaceuticals</title></head><body><p><span>Aug 25 (Reuters)</span><span> - </span>MannKind Corp <span>MNKD.O</span>:</p><ul><li><p>MANNKIND TO ACQUIRE SCPHARMACEUTICALS, ACCELERATING REVENUE GROWTH AND EMERGING AS A PATIENT-CENTRIC LEADER IN CARDIOMETABOLIC AND LUNG DISEASES</p></li><li><p>MANNKIND CORP - DEAL FOR UPFRONT CASH PAYMENT OF $5.35 PER SHARE PLUS CVR</p></li><li><p>MANNKIND CORP - TOTAL EQUITY VALUE $303 MILLION, DEAL VALUE UP TO $360 MILLION</p></li><li><p>MANNKIND CORP - CO AND BLACKSTONE AMEND FINANCING AGREEMENT FOR $175 MILLION</p></li></ul><p>Source text: <span>ID:nGNX4Dd9pp</span></p><p>Further company coverage: <span>MNKD.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SCPH","symbol_name":"Scpharmaceuticals Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250825:nTUA8WGSQS:1","article_id":"2562324652","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2562324652","pubTimestamp":1756121629,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-MannKind To Acquire scPharmaceuticalsAug 25 (Reuters) - MannKind Corp MNKD.O:MANNKIND TO ACQUIRE SCPHARMACEUTICALS, ACCELERATING REVENUE GROWTH AND EMERGING AS A PATIENT-CENTRIC LEADER IN CARDIO","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SCPH":"Scpharmaceuticals Inc.","BK4007":"制药","BK4584":"避孕概念","MNKD":"曼恩凯德生物医疗","BK4139":"生物科技"},"translate_title":"简介-MannKind将收购scPharmaceuticals","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MNKD":0.9,"SCPH":0.9},"content_text":"BRIEF-MannKind To Acquire scPharmaceuticalsAug 25 (Reuters) - MannKind Corp MNKD.O:MANNKIND TO ACQUIRE SCPHARMACEUTICALS, ACCELERATING REVENUE GROWTH AND EMERGING AS A PATIENT-CENTRIC LEADER IN CARDIOMETABOLIC AND LUNG DISEASESMANNKIND CORP - DEAL FOR UPFRONT CASH PAYMENT OF $5.35 PER SHARE PLUS CVRMANNKIND CORP - TOTAL EQUITY VALUE $303 MILLION, DEAL VALUE UP TO $360 MILLIONMANNKIND CORP - CO AND BLACKSTONE AMEND FINANCING AGREEMENT FOR $175 MILLIONSource text: ID:nGNX4Dd9ppFurther company coverage: MNKD.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2562324652","isCrawlerRequest":true}